Dec 15, 2022 / 09:30AM GMT
Clive Dix - C4X Discovery Holdings plc - Interim Executive Chairman & CEO
Thank you. And good morning, everybody, and welcome to this briefing. I'm joined today by Bhavna Hunjan, our Chief Business Officer.
And if we move to the next slide, I'll hand over to Bhavna to start going through the current agreement that we just announced.
Bhavna Hunjan - C4X Discovery Holdings plc - Chief Business Officer
Good morning, everyone, and welcome. So today, we have announced up to $402 million licensing agreement, which is a worldwide exclusive license to AstraZeneca to take forward our NRF2 Activator program. It's an incredibly exciting moment for C4X. And we are pleased to say that the total deal value includes $16 million of preclinical payments, and that includes a $2 million upfront.
There are also mid-single digit royalties associated with the deal. This is our third major licensing deal on a program at C4X within a five-year period. And the total potential revenue associated with these deals tops close to $1.2 billion, which is a hugely
Full Year 2022 C4X Discovery Holdings PLC Earnings Call Transcript
Dec 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers